%0 Journal Article
%A Afshar-Oromieh, Ali
%A Debus, Nils
%A Uhrig, Monika
%A Hope, Thomas A
%A Evans, Michael J
%A Holland-Letz, Tim
%A Giesel, Frederik L
%A Kopka, Klaus
%A Hadaschik, Boris
%A Kratochwil, Clemens
%A Haberkorn, Uwe
%T Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.060
%J European journal of nuclear medicine and molecular imaging
%V 45
%N 12
%@ 1619-7089
%C Heidelberg [u.a.]
%I Springer-Verl.
%M DKFZ-2018-01698
%P 2045 - 2054
%D 2018
%X Since the introduction of PSMA PET/CT with 68Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly increase PSMA expression on PC cells. Additionally, retrospective clinical data in large patient cohorts suggest a positive association between ongoing ADT and a pathological PSMA PET/CT scan. The present evaluation was conducted to further analyse the influence of long-term ADT on PSMA PET/CT findings.A retrospective analysis was performed of all 1,704 patients who underwent a 68Ga-PSMA-11 PET/CT scan at our institution from 2011 to 2017 to detect PC. Of 306 patients scanned at least twice, 10 had started and continued ADT with a continuous clinical response between the two PSMA PET/CT scans. These ten patients were included in the current analysis which compared the tracer uptake intensity and volume of PC lesions on PSMA PET/CT before and during ongoing ADT.Overall, 31 PC lesions were visible in all ten patients before initiation of ADT. However, during ongoing ADT (duration 42-369 days, median 230 days), only 14 lesions were visible in eight of the ten patients. The average tracer uptake values decreased in 71
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29980832
%2 pmc:PMC6182397
%R 10.1007/s00259-018-4079-z
%U https://inrepo02.dkfz.de/record/141171